Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 12/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | EIF2AK3 | Q9NZJ5 | 2/20 | 0.36 |
| ▸ | ABL1 | P00519 | 3/20 | 0.36 |
| ▸ | SRC | P12931 | 3/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.36 |
| ▸ | PAK4 | O96013 | 2/20 | 0.36 |
| ▸ | LCK | P06239 | 2/20 | 0.36 |
| ▸ | FYN | P06241 | 2/20 | 0.36 |
| ▸ | CSF1R | P07333 | 2/20 | 0.36 |
| ▸ | RET | P07949 | 2/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.36 |
| ▸ | FLT1 | P17948 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | FLT3 | P36888 | 2/20 | 0.36 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.36 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.36 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6866845 | 0.95 | ADK (0.47) | ADKSLC29A1EIF2AK3ABL1SRC | |
| SCHEMBL20351805 | 0.95 | ADK (0.47) | ADKSLC29A1EIF2AK3ABL1SRC | |
| SCHEMBL16236581 | 0.92 | ADK (0.49) | ADKSLC29A1MTORRAB9A | |
| SCHEMBL2969987 | 0.90 | ADK (0.47) | ADKSLC29A1EIF2AK3ABL1SRC | |
| SCHEMBL2969985 | 0.90 | ADK (0.47) | ADKSLC29A1EIF2AK3ABL1SRC | |
| SCHEMBL6866005 | 0.90 | ADK (0.47) | ADKSLC29A1EIF2AK3ABL1SRC | |
| SCHEMBL16236390 | 0.89 | ADK (0.54) | ADKSLC29A1ABL1SRCMAP4K4 | |
| SCHEMBL29484542 | 0.89 | ADK (0.54) | ADKSLC29A1ABL1SRCMAP4K4 | |
| SCHEMBL21084208 | 0.86 | ADK (0.48) | ADKSLC29A1EIF2AK3ABL1SRC | |
| SCHEMBL401328 | 0.86 | ADK (0.52) | ADKSLC29A1ABL1SRCMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833153-B2 | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-12-05 | — | — | US | disclosed |
| EP-3472165-B1 | N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2023-09-06 | — | — | EP | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230107393-A1 | N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-04-06 | — | — | US | disclosed |
| CN-115843272-A | Inhibitors of NEK7 kinase | 哈利亚治疗公司 | 2023-03-24 | — | — | CN | disclosed |
| US-20200121686-A1 | N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2020-04-23 | — | — | US | disclosed |
| US-10561660-B2 | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2020-02-18 | — | — | US | disclosed |
| US-20190201406-A1 | N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-07-04 | — | — | US | disclosed |
| EP-3472165-A1 | N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2019-04-24 | — | — | EP | disclosed |
| WO-2018121228-A1 | COMPOUND HAVING AXL INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2018-07-05 | — | — | WO | disclosed |
| EP-3067356-B1 | PYRROLO PYRIMIDINE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2018-07-04 | — | — | EP | disclosed |
| WO-2017220477-A1 | N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-12-28 | — | — | WO | disclosed |
| US-9586967-B2 | Pyrrolo pyrimidine derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-03-07 | — | — | US | disclosed |
| US-20160264579-A1 | PYRROLO PYRIMIDINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-09-15 | — | — | US | disclosed |
| EP-3067356-A1 | PYRROLO PYRIMIDINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2016-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230107393-A1 | N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS | ATF4, MAP3K1, MAP3K6 | ADK 361/4885SLC29A1 3337/4885EIF2AK3 58/4885 |
| US-20160264579-A1 | PYRROLO PYRIMIDINE DERIVATIVE | AXL, FLT3, TYRO3 | ADK 282/4885SLC29A1 3249/4885EIF2AK3 3278/4885 |
| US-20190201406-A1 | N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS | ATF4, MAP3K1, MAP3K6 | ADK 361/4885SLC29A1 3337/4885EIF2AK3 58/4885 |
| US-11713321-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | ADK 72/4885SLC29A1 1626/4885EIF2AK3 1245/4885 |
| US-11833153-B2 | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors | ATF4, MAP3K1, MAP3K6 | ADK 361/4885SLC29A1 3337/4885EIF2AK3 58/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | ADK 286/4885SLC29A1 2077/4885EIF2AK3 1310/4885 |
| US-20200121686-A1 | N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS | ATF4, MAP3K1, MAP3K6 | ADK 361/4885SLC29A1 3337/4885EIF2AK3 58/4885 |
| US-10561660-B2 | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors | ATF4, MAP3K1, MAP3K6 | ADK 361/4885SLC29A1 3337/4885EIF2AK3 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.